Stratégies thérapeutiques ciblant la voie KRAS dans le cancer bronchique non à petites cellules.

S. Le Moulec; Y. Loriot; J. C. Soria

doi:10.1684/bdc.2009.0998

Stratégies thérapeutiques ciblant la voie KRAS dans le cancer bronchique non à petites cellules.

Translated title of the contribution: Targeting KRAS pathway in NSCLC therapy

S. Le Moulec, Y. Loriot, J. C. Soria

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

KRAS mutations are currently the most frequently mutated oncogenes in non-small cell lung cancers (NSCLC). A growing body of evidence suggests that targeting RAS could be an efficient strategy in NSCLC. Several approaches have been developed to target either RAS protein or downstream effectors such as RAF or MEK. First clinical trials evaluating farnesyltransferases inhibitors have led to unsuccessful results. However, targeting RAF and MEK could be a more efficient approach in NSCLC.

Translated title of the contribution	Targeting KRAS pathway in NSCLC therapy
Original language	French
Pages (from-to)	S69-74
Journal	Bulletin du Cancer
Volume	96 Suppl
DOIs	https://doi.org/10.1684/bdc.2009.0998
Publication status	Published - 1 Jan 2009

Access to Document

10.1684/bdc.2009.0998

Cite this

@article{a54f4625bf014bebb62e616e44ad0d53,

title = "Strat{\'e}gies th{\'e}rapeutiques ciblant la voie KRAS dans le cancer bronchique non {\`a} petites cellules.",

abstract = "KRAS mutations are currently the most frequently mutated oncogenes in non-small cell lung cancers (NSCLC). A growing body of evidence suggests that targeting RAS could be an efficient strategy in NSCLC. Several approaches have been developed to target either RAS protein or downstream effectors such as RAF or MEK. First clinical trials evaluating farnesyltransferases inhibitors have led to unsuccessful results. However, targeting RAF and MEK could be a more efficient approach in NSCLC.",

author = "{Le Moulec}, S. and Y. Loriot and Soria, {J. C.}",

year = "2009",

month = jan,

day = "1",

doi = "10.1684/bdc.2009.0998",

language = "Fran{\c c}ais",

volume = "96 Suppl",

pages = "S69--74",

journal = "Bulletin du Cancer",

issn = "0007-4551",

}

TY - JOUR

T1 - Stratégies thérapeutiques ciblant la voie KRAS dans le cancer bronchique non à petites cellules.

AU - Le Moulec, S.

AU - Loriot, Y.

AU - Soria, J. C.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - KRAS mutations are currently the most frequently mutated oncogenes in non-small cell lung cancers (NSCLC). A growing body of evidence suggests that targeting RAS could be an efficient strategy in NSCLC. Several approaches have been developed to target either RAS protein or downstream effectors such as RAF or MEK. First clinical trials evaluating farnesyltransferases inhibitors have led to unsuccessful results. However, targeting RAF and MEK could be a more efficient approach in NSCLC.

AB - KRAS mutations are currently the most frequently mutated oncogenes in non-small cell lung cancers (NSCLC). A growing body of evidence suggests that targeting RAS could be an efficient strategy in NSCLC. Several approaches have been developed to target either RAS protein or downstream effectors such as RAF or MEK. First clinical trials evaluating farnesyltransferases inhibitors have led to unsuccessful results. However, targeting RAF and MEK could be a more efficient approach in NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=75549083475&partnerID=8YFLogxK

U2 - 10.1684/bdc.2009.0998

DO - 10.1684/bdc.2009.0998

M3 - Article

C2 - 20034872

AN - SCOPUS:75549083475

SN - 0007-4551

VL - 96 Suppl

SP - S69-74

JO - Bulletin du Cancer

JF - Bulletin du Cancer

ER -

Stratégies thérapeutiques ciblant la voie KRAS dans le cancer bronchique non à petites cellules.

Abstract

Access to Document

Other files and links

Cite this